Pi-Cardia
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5 David Fikes St, Rehovot, Central Distr...Phone Number
+972 89484800Website
www.pi-cardia.netRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Pi-Cardia
Pi-Cardia specializes in next-generation valve repair solutions for structural heart disease, offering unique non-implant-based catheter treatments. Their portfolio includes the Leaflex Performer and ShortCut Device, designed for safe, effective, and affordable procedures with short hospital stays. The company targets healthcare providers and patients in need of innovative heart valve treatments. Pi-Cardia's technologies aim to address unmet medical needs while ensuring excellent safety and efficacy outcomes.Explore more
Pi-Cardia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pi-Cardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Pi-Cardia has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pi-Cardia has new funding data
Check out if Pi-Cardia is spiking on competitors!
Pi-Cardia, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Pi-Cardia
Earning: See what the market has to say on Pi-Cardia recently announced quarterly report
Click to see if Pi-Cardia had a recent Job posting/layoffs
Product Launch: Get notified when Pi-Cardia launches new products
Recommended Actions
Find VP level buyers at Pi-Cardia
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pi-Cardia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pi-Cardia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pi-Cardia.
Pi-Cardia financials insights
Gather financial insights about Pi-Cardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$27M
Pi-Cardia Tech Stack
A closer look at the technologies used by Pi-Cardia
Pi-Cardia News & Media
Pi-Cardia Receives FDA Market Clearance for ShortCut™
REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market clearance for ShortCut™ - the world's first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction. “Lifetime management of aortic stenosis calls for leafPi-Cardia Receives FDA Breakthrough Device Designation for ShortCut™
REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia receives Breakthrough Device Designation from the US FDA for ShortCut™ device facilitating valve-in-valve TAVR in coronary risk patients.Pi-Cardia Hires Gary Gratson to Lead Global Commercialization
REHOVOT, Israel--(BUSINESS WIRE)-- #PiCardia--Pi-Cardia, a leader in non-implant solutions for heart valves treatment , announces Gary Gratson to lead commercial operations for ShortCut™ device.Pi-Cardia Successfully Completes Enrollment in Pivotal Study for ShortCut™
REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today the successful completion of its ShortCut™ Pivotal Study enrollment. ShortCut™ is the world's first dedicated device designed to split the leaflets of pre-existing valves to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk of coronary obstruction. The study was conducted across
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pi-Cardia
Sign Up For FreeTo access detailed company insights
Pi-Cardia specializes in next-generation valve repair solutions for structural heart disease, offering unique non-implant-based catheter treatments. Their portfolio includes the Leaflex Performer and ShortCut Device, designed for safe, effective, and affordable procedures with short hospital stays. The company targets healthcare providers and patie... Read More
